TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21543960

Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Arm ergometry
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 41
Study: 19467544

Group type: EXPERIMENTAL
Intervention: rG‐CSF (10 microg/kg/day) for 3 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 16432054

Group type: EXPERIMENTAL
Intervention: L-arginine + ramipril
Number of subjects: 17

Group type: COMPARATOR
Intervention: L-NG-nitro-arginine-methyl-ester (2 mg/kg) during ramipril
Number of subjects: 17
Study: 14768658

Group type: EXPERIMENTAL
Intervention: Cafeteria-based intervention including daily activities to increase availability, attractiveness, and encouragement for fruit and vegetable consumption, along with special events over two school years.
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 1668
Study: 11765593

Group type: EXPERIMENTAL
Intervention: Prednisolone 50 mg Ferring tablets (test preparation)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Reference preparation (control)
Number of subjects: 13
Study: 9239399

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg daily for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8393019

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (3 x 4 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3722617

Group type: COMPARATOR
Intervention: Immediate reward completion in hyperactive children
Number of subjects: 32

Group type: COMPARATOR
Intervention: Short-active delay trial
Number of subjects: 32
Study: 30251109

Group type: EXPERIMENTAL
Intervention: Aerobic exercise programs + hypocaloric diet
Number of subjects: 167
Study: 25842202

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (demographically similar, N = 32, scanned twice)
Number of subjects: 43
Study: 24515256

Group type: EXPERIMENTAL
Intervention: Lifestyle counseling (LC) plus metformin (target dose of 1,000 mg twice daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lifestyle counseling (LC) only
Number of subjects: 54
Study: 22505373

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 300 mg q.i.d., esomeprazole 40 mg b.i.d., tetracycline 500 mg q.i.d., and amoxicillin 1 g b.i.d. (bismuth group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg b.i.d., tetracycline 500 mg q.i.d., amoxicillin 1 g b.i.d., and metronidazole 500 mg t.i.d. (concomitant group)
Number of subjects: 200
Study: 20386337

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (PA)
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Accelerometer-measured moderate- to vigorous-intensity PA (MVPA)
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Accelerometer-measured vigorous-intensity PA (VPA)
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Diabetes medication usage and history of cardiovascular disease
Number of subjects: 2240
Study: 18471061

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (vitamins A, B complex, C, E, and selenium)
Number of subjects: 887
Study: 15598945

Group type: EXPERIMENTAL
Intervention: Vinorelbine-Gemcitabine (VG)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Carboplatin-Paclitaxel (CP)
Number of subjects: 165
Study: 12859471

Group type: EXPERIMENTAL
Intervention: 15 ml.kg‐1 Hartmann's solution (supplemental fluid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2 ml.kg‐1 Hartmann's solution (conservative fluid)
Number of subjects: 80
Study: 10690832

Group type: EXPERIMENTAL
Intervention: Intravenous broad-spectrum antibiotic immediately after induction of anesthesia (group 1)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Intraoperative lavage of the rhinostomy site just after suture of the anterior mucosal flaps (group 2)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Postoperative course of oral antibiotics (group 3)
Number of subjects: 265
Study: 8645644

Group type: EXPERIMENTAL
Intervention: Fish oil (2.7 g/day n‐3 fatty acids)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Control (olive oil or no oil supplementation)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 533
Study: 1825475

Group type: EXPERIMENTAL
Intervention: CP + SR-2508
Number of subjects: 39

Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SR-2508
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CP
Number of subjects: 39
Study: 6823925

Group type: EXPERIMENTAL
Intervention: Furazolidone for ten days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Furazolidone for five days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Furazolidone for ten days (retreatment)
Number of subjects: 22
Study: 31881990

Group type: EXPERIMENTAL
Intervention: Physiotherapy Activity and Awareness Intervention (PAAI) for 8 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques (TRT) for 6 weeks
Number of subjects: 146

Group type: COMPARATOR
Intervention: Delayed intervention group for both PAAI and TRT
Number of subjects: 146
Study: 29953304

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Internet-Based Mindfulness-Based Cognitive Therapy (eMBCT)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 245
Study: 27621609

Group type: EXPERIMENTAL
Intervention: Albuterol (4×100 μg/puff in the UK; 4×90 μg/puff in the US)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ipratropium (4×20 μg/puff)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 54
Study: 23663079

Group type: EXPERIMENTAL
Intervention: Sedative music played for the first hour in bed
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (without music)
Number of subjects: 24
Study: 21492253

Group type: EXPERIMENTAL
Intervention: Lidocaine-diluted BTX-A
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline-diluted BTX-A
Number of subjects: 8
Study: 18925392

Group type: EXPERIMENTAL
Intervention: Recombinant IL-21 (rIL-21) administered by intravenous bolus injection at dose levels from 1 to 100 microg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 + 9 dosing regimen of rIL-21
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3/w dosing regimen of rIL-21
Number of subjects: 0
Study: 17342356

Group type: EXPERIMENTAL
Intervention: Sternal closure with corpus sterni reinforcement (group 2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard sternal closure techniques (group 1)
Number of subjects: 71
Study: 15378666

Group type: EXPERIMENTAL
Intervention: milnacipran (up to 200 mg/day)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: milnacipran (twice daily)
Number of subjects: 125

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study: 11556124

Group type: COMPARATOR
Intervention: 10 x 2 mg prednisolone tablets
Number of subjects: 13

Group type: COMPARATOR
Intervention: 4 x 5 mg prednisolone tablets
Number of subjects: 13

Group type: COMPARATOR
Intervention: 20 mg prednisolone tablet formulation
Number of subjects: 13
Study: 9748025

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study: 7833518

Group type: EXPERIMENTAL
Intervention: Absorbable clips
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metal clips
Number of subjects: 50
Study: 3416729

Group type: EXPERIMENTAL
Intervention: Alcohol doses (0.25, 0.5 and 0.75 g/kg of 95% ethanol)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 4
Study: 31204824

Group type: EXPERIMENTAL
Intervention: PFI-NAC (1-session personalized feedback intervention)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 63
Study: 29900909

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (scaling and root planning)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy periodontium (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chronic generalized periodontitis (Group II) before treatment
Number of subjects: 30
Study: 27404009

Group type: EXPERIMENTAL
Intervention: Smartphone raffle intervention (weekly for clients, monthly for peer promoters and providers)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Smartphone raffle intervention (Iringa region subanalysis)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (Iringa region subanalysis)
Number of subjects: 7
Study: 24096084

Group type: EXPERIMENTAL
Intervention: Purported weight-loss supplement (placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 21443756

Group type: EXPERIMENTAL
Intervention: Cream A [3% PLA-retinyl retinoate (2%) microsphere] applied twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cream B (0.06% retinyl retinoate) applied twice daily
Number of subjects: 44
Study: 20108154

Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 89
Study: 18753058

Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment with directional soft tube placement
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conservative treatment (medication)
Number of subjects: 75
Study: 15802855

Group type: EXPERIMENTAL
Intervention: Misasa hot spring district residents (exposed to radon)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control district residents
Number of subjects: 0
Study: 12091260

Group type: EXPERIMENTAL
Intervention: Citalopram 20-40 mg for 8 weeks followed by 16 weeks of fixed dose and then randomisation to citalopram for at least 48 weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo for at least 48 weeks
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 121
Study: 11185677

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8543937

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Theophylline 150 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2037418

Group type: EXPERIMENTAL
Intervention: Phenol treatment on tympanic membrane prior to myringotomy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no phenol treatment)
Number of subjects: 46
Study: 7016224

Group type: COMPARATOR
Intervention: Chemotherapy and radiation therapy alone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy plus living BCG vaccinations
Number of subjects: 77
Study: 30475753

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Occlusal splint (OS)
Number of subjects: 34
Study: 28115667

Group type: EXPERIMENTAL
Intervention: 25 mg of zinc
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: 2,500 IU of vitamin A
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Both 2,500 IU of vitamin A and 25 mg of zinc
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 25887759

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) with a decision support tool and 2-hour training for GPs
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group continuing with the treatment allocated in the ADDITION study
Number of subjects: 150
Study: 24225157

Group type: EXPERIMENTAL
Intervention: SOX plus bevacizumab
Number of subjects: 512

Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab
Number of subjects: 512
Study: 21884578

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: All SGAs (Olanzapine, Quetiapine, Risperidone, Ziprasidone)
Number of subjects: 226
Study: 19595568

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 190
Study: 15972619

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 50 mg injections every 3 weeks
Number of subjects: 65
Study: 12812849

Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiotherapy (SRT) boost to 20 Gy in four fractions following partial brain irradiation to a dose of 60 Gy in 30 fractions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiotherapy (SRT) boost to 10 Gy (2 patients)
Number of subjects: 17
Study: 10319907

Group type: EXPERIMENTAL
Intervention: Haloperidol 30 mg/day plus cyproheptadine 24 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Haloperidol 30 mg/day plus placebo
Number of subjects: 30
Study: 8532270

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg, three times per day from 36 weeks' gestation until delivery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo, three times per day from 36 weeks' gestation until delivery
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 1747891

Group type: EXPERIMENTAL
Intervention: Intensified prevention program (Group 2)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Standard preventive care (Group 1)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Low-risk group (Group 3)
Number of subjects: 323
Study: 6356974

Group type: EXPERIMENTAL
Intervention: Oral lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31112373

Group type: EXPERIMENTAL
Intervention: Nomograms for predicting overall survival (OS)
Number of subjects: 4175

Group type: EXPERIMENTAL
Intervention: Nomograms for predicting cancer-specific survival (CSS)
Number of subjects: 4175
Study: 28402351

Group type: EXPERIMENTAL
Intervention: Placement of deproteinized bovine bone mineral (DBBM; Endobon) covered with a soft tissue punch from the palate (Tx1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Placement of DBBM without soft tissue punch (Tx2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Placement of an adsorbable collagen membrane (Osseoguard) covering the DBBM (Tx3)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No additional treatment (control)
Number of subjects: 35
Study: 26304905

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gabapentin (GP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo pills (PP)
Number of subjects: 120
Study: 23701770

Group type: EXPERIMENTAL
Intervention: Early feeding (Group 1), starting feeds 24h post-operation with a protocol driven increase
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (Group 2), managed without a specific protocol
Number of subjects: 31
Study: 21143248

Group type: EXPERIMENTAL
Intervention: L-cysteine (200 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 19321405

Group type: EXPERIMENTAL
Intervention: Locally applied gentamicin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Intravenous gentamicin
Number of subjects: 202
Study: 17156222

Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg administered intravenously 30 min before the end of surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ondansetron 4 mg administered intravenously 30 min before the end of surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam and Ondansetron
Number of subjects: 90
Study: 15996249

Group type: EXPERIMENTAL
Intervention: Elevated serum creatinine
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Graft loss
Number of subjects: 1052
Study: 12441833

Group type: EXPERIMENTAL
Intervention: Eccentric exercise at 80% of maximal voluntary concentric strength (n = 45)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Eccentric exercise at 100% of maximal voluntary concentric strength (n = 36)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Eccentric exercise at 120% of maximal voluntary concentric strength (n = 30)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resting blood pressure measurements averaged over 6 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of pain intensity ratings between sexes
Number of subjects: 42
Study: 10501408

Group type: EXPERIMENTAL
Intervention: Combination of antioxidants, niacin, and warfarin
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Active niacin group
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Overall compliance
Number of subjects: 468
Study: 8604625

Group type: EXPERIMENTAL
Intervention: Non-Q-wave infarction
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Q-wave infarction
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control patients without recent infarction
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Peak creatine phosphokinase levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Change in left ventricular end-diastolic index
Number of subjects: 45
Study: 1681430

Group type: EXPERIMENTAL
Intervention: Isoniazid (up to 1,200 mg daily) with 100 mg pyridoxine for four weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study: 6125276

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine treated group
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Saline group
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 220
Study: 30328031

Group type: EXPERIMENTAL
Intervention: 6 mg melatonin once a day
Number of subjects: 50
Study: 30033435

Group type: EXPERIMENTAL
Intervention: Culturally and linguistically tailored breast cancer education program
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209
Study: 27588701

Group type: EXPERIMENTAL
Intervention: Naltrexone 50mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24439959

Group type: EXPERIMENTAL
Intervention: Right‐sided rTMS to VLPFC
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Right‐sided rTMS to TPJ
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (not receiving rTMS)
Number of subjects: 17
Study: 22207227

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 310
Study: 20976430

Group type: EXPERIMENTAL
Intervention: Home visiting program 'Pro Kind' (treatment group)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Standard community service (control group)
Number of subjects: 755
Study: 17517002

Group type: EXPERIMENTAL
Intervention: Early childhood intervention (Abecedarian study)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no early childhood intervention)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Early childhood intervention
Number of subjects: 104
Study: 16366815

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nicotine gum (0 mg)
Number of subjects: 20
Study: 12068793

Group type: EXPERIMENTAL
Intervention: CEOP (cyclophosphamide 1000mg m(‐2), vincristine 2mg, epirubicin 70mg m(‐2) on day 1, prednisone 60mg on days 1‐7)
Number of subjects: 249

Group type: COMPARATOR
Intervention: CNOP (cyclophosphamide 1000mg m(‐2), vincristine 2mg, mitoxantrone 12mg m(‐2) on day 1, prednisone 60mg on days 1‐7)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Both CEOP and CNOP
Number of subjects: 249
Study: 9851759

Group type: EXPERIMENTAL
Intervention: Testosterone administration (300 mg, im, every 3 weeks for 6 months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 51
Study: 7879301

Group type: EXPERIMENTAL
Intervention: High-fat diet rich in monounsaturated fat
Number of subjects: 0
Study: 2212203

Group type: EXPERIMENTAL
Intervention: Tripton/Occlusin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: XR Bond/Herculite XR
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gluma/Lumifor
Number of subjects: 50

Group type: COMPARATOR
Intervention: Scotchbond 2/P50
Number of subjects: 50

Group type: COMPARATOR
Intervention: Superbond C & B/Occlusin
Number of subjects: 50
Study: 105099

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Levamisole (after switching from placebo)
Number of subjects: 65
Study: 29278555

Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre (RM-group, n=21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard protective ventilation (C-group, n=21)
Number of subjects: 42
Study: 26869247

Group type: EXPERIMENTAL
Intervention: 2 mg/2 mg buprenorphine/samidorphan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8 mg/8 mg buprenorphine/samidorphan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24980134

Group type: EXPERIMENTAL
Intervention: Moderate-fat diet containing pistachios (20% of total energy) for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-fat control diet (27% fat) for 4 weeks
Number of subjects: 30
Study: 22302908

Group type: EXPERIMENTAL
Intervention: Gabapentin (oral dose before surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no gabapentin)
Number of subjects: 0
Study: 20721445

Group type: EXPERIMENTAL
Intervention: Direct immunofluorescence assay (DFA)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Real-time polymerase chain reaction (RT-PCR)
Number of subjects: 291